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Abstract: Introduction: Finding a fast-acting compound with minimal side-effects to induce a safe and efficient anal-
gesia with short or medium duration of action is of great interest in the emergency department. The present
study has been designed with the aim of comparing the effect of midazolam + fentanyl + lidocaine combination
with midazolam + fentanyl + placebo in pain management of anterior shoulder dislocation reduction. Meth-
ods: The present two-arm parallel double-blind randomized controlled trial was performed on patients who
presented to emergency department with anterior shoulder dislocation. Patients were randomly allocated to
the 2 treatment groups of midazolam + fentanyl + placebo (double-drug group) and midazolam + fentanyl +
intravenous (IV) lidocaine (triple-drug group). Then outcomes such as treatment success rate and side-effects
following prescription of drugs were compared between the 2 groups. Results: 100 patients were included in the
present study (50 patients in each group; mean age of the studied patients 27.3±8.9 years; 93.0% male). Using
the double-drug regimen led to 35 (70%) cases of complete analgesia, while this rate in the triple-drug group was
41 (82%) cases (p=0.16). The calculated number needed to treat was 9 cases. This means that about one in every
9 patients in treatment arm will benefit from the treatment. The most important side-effects observed included
dysrhythmia (1 patient in double drug and 1 patient in triple-drug group), apnea (2 patients in each group) and
SPO2<90% (2 patients in triple-drug group) (p=0.78). Number needed to harm was 25 cases. In other words, for
each 25 patients treated with the triple drug regimen, 1 case of SPO2<90% is observed. Conclusion: Findings
of the present study showed that adding IV lidocaine to IV midazolam + fentanyl drug combination does not
provide additional analgesia in sedation for anterior shoulder reduction.
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1. Introduction
O
ne of the painful treatment interventions in need of
procedural sedation and analgesia (PSA) is reduction
of anterior shoulder dislocation and the statistics are
indicative of its 1 - 1.7% prevalence in societies. The preva-
lence of these dislocations is higher among those in the age
range of 20 – 30 years and affects men more than women
(1). Using a proper analgesia method for controlling the pain
of these patients during reduction is of great interest (2-4).
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For this purpose, emergency medicine specialists are con-
stantly seeking a fast-acting compound with minimal side-
effects to induce a safe and efficient analgesia with short or
medium duration of action in patients. The first suggested
protocols of PSA were based on single-drug strategies, which
had a strong emphasis on using opioids, propofol, midazo-
lam, or fentanyl alone (5). However, for achieving lasting se-
dation in these single-drug protocols, a high dose of the men-
tioned drugs were required, which would result in serious
side-effects such as depression of the central nervous system
(CNS), apnea and dangerous hypoxia (6). Sometimes, there
would be cases that even by using the highest dose allowed,
proper sedation would not be induced (7, 8).
Therefore, to relieve this deficiency, the researchers turned to
double-drug strategies so that they could not only reduce the
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dose of consumption for each drug, but also achieve double
effectiveness by using drugs that have different mechanisms
of action. Among these drug combinations are propofol + mi-
dazolam, propofol + fentanyl, midazolam + fentanyl, and etc.
(9-17).
However, these double-drug protocols also have limitations,
among which are lack of complete effectiveness and consid-
erable treatment failures in patients (6). Therefore, it is pos-
sible that adding another drug to these treatment protocols
improves the effectiveness and reduces the side-effects. Li-
docaine is an anesthetic drug, intravenous (IV) prescription
of which can control pains due to cancer, post-surgery pains,
and neuropathic pains (18). Lidocaine reduces pain in pa-
tients by decreasing the sensitivity and activity of neurons
that transmit pain in the CNS and decreasing post-synaptic
receptors of N-methyl-d-aspartate (19-21). Although the ef-
fectiveness of local prescription of lidocaine (intra-articular)
in controlling the pain following shoulder reduction has been
confirmed in a meta-analysis (22), its analgesic effects fol-
lowing IV prescription is less known. On the other hand, no
study has been done with the aim of assessing the additive
or synergic effects of using lidocaine along with midazolam +
fentanyl combination, yet. Therefore, the present study was
designed with the aim of comparing the effect of IV mida-
zolam + fentanyl + lidocaine combination with midazolam +
fentanyl + placebo as PSA for reduction of anterior shoulder
dislocation in emergency department.
2. Methods
2.1. Study design and setting
The present two-arm parallel double-blind randomized con-
trolled trial was performed on patients who presented to
the emergency departments of Imam Hossein, Loghmane
Hakim, and Shohadaye Tajrish Hospitals, Tehran, Iran, with
anterior shoulder dislocation throughout 2016. The study
was approved by the ethics committee of Shahid Beheshti
University of Medical Sciences and patients were included
after obtaining informed consent from the patient or their
companion. The researchers adhered to the principles indi-
cated in the declaration of Helsinki throughout the study. It
should be noted that the protocol of the present study was
registered on the Iranian Registry of Clinical Trials under the
number IRCT2016101730353N1.
2.2. Participants
Patients with anterior shoulder dislocation candidate for re-
duction were included in the study. Patients with altered level
of consciousness at the time of presentation, those who had
a fracture in their shoulder joint along with shoulder disloca-
tion (apart from Lesion Sachs-Hill), patients with a history of
surgery on the same shoulder joint or fracture of the shoul-
der joint, history of seizure, those who had received anal-
gesic drugs before presenting, patients with history of car-
diac diseases and dysrhythmia, history of taking digoxin, and
patients with a history of allergy to lidocaine, midazolam, or
fentanyl were excluded from the study.
2.3. Interventions
Using a web-based program and via block randomization
method (with block size of 5) without stratifying for base-
line characteristics, the studied patients were allocated to the
2 treatment groups of IV midazolam + fentanyl + placebo
(double-drug group) and IV midazolam + fentanyl + lido-
caine (triple-drug group). Randomization was performed
by a statistics expert who did not participate in the pro-
cess of sampling and evaluating the outcome of the patients.
Drugs were prepared as anonymous, colorless, and odor-
less packs by a senior researcher that played no part in the
treatment process and follow-up of the patients and were
given to a third year emergency medicine resident who was
in charge of prescribing the drugs and evaluating the pain of
the patients. Before starting therapeutic intervention, base-
line characteristics of the patients including age, sex, weight,
history of smoking, history of taking opium, history of alco-
hol consumption, and history of being affected with under-
lying illnesses would be recorded. Then, using Visual analog
scale (VAS), pain of the patients was assessed and recorded.
Before initiation of sedation, patients underwent hemody-
namic evaluation and continuous pulse oximetry and 3 liters
of nasal oxygen (their arterial oxygen saturation level would
be maintained over 95%).
In case of no initial problem, 1 mg/kg lidocaine for patients
in the triple-drug group and distilled water (as placebo) in
the double-drug group were prescribed intravenously. Then
both mentioned groups were given midazolam and fentanyl
by injection in a titrated manner until the analgesia of the pa-
tient reached the score of 4 based on Ramsay sedation scale
(23). If the patient did not reach the score of 4 despite re-
ceiving the maximum allowed dose of the drugs, the case was
recorded as a case of failure in sedation and included in the
analyses. After the patient reached the score of 4 based on
Ramsey scale, the midazolam and fentanyl dose used was
recorded for each patient and shoulder reduction was per-
formed. After the patient became completely conscious, pain
severity was evaluated and recorded based on VAS.
2.4. Evaluated outcomes
The primary outcome evaluated in this study was considered
treatment success rate. For this purpose, complete analgesia
(VAS=0) of the patient after reduction was defined as treat-
ment success. The secondary outcome in the present study
was considered the evaluation of side-effects following pre-
scription of drugs including dysrhythmia, apnea, hypoxia,
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flowchart 1: Flowchart of present study.
nausea and vomiting, and other side-effects. In the end, the
final dose of fentanyl and midazolam used in the 2 studied
groups was evaluated.
2.5. Statistical Analysis
Since in the beginning of the present research there was no
similar study, a pilot study was performed on 10 patients to
determine sample size based on it. Mean pain severity of pa-
tients after reduction in the pilot study was 1.33 ± 0.82 in the
double-drug group and 0.82 ± 0.71 in the triple-drug group.
Therefore, by considering 90% power (β=0.1) and 95% confi-
dence interval (α=0.05), 49 patients in each group was suffi-
cient for the present study, and in the end, 50 patients were
included in each group. Data were entered to STATA 14.0
statistical software and analyzed. Quantitative data were re-
ported as mean and standard deviation and qualitative data
were reported as frequency and percentage. To compare
quantitative data between the 2 studied groups, indepen-
dent t-test and for comparing qualitative data, chi square or
Fisher’s exact test were used. In addition, based on com-
plete analgesia, treatment success was calculated and num-
ber needed to treat, number needed to harm, absolute risk
reduction and relative risk reduction were calculated based
on it. In all analyses p<0.05 was considered as the level of
significance.
3. Results
In the end, data of 100 patients were included in the present
study (50 patients in each group; flowchart 1). Mean age of
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Table 1: Baseline characteristics of included patients
Variable Double-drug group (n=50) Triple-drug group (n=50) Total (n=100) P
Age (year) 27.7±8.7 27.0±9.2 27.3±8.9 0.71
Sex
Male 48 (96.0) 45 (90.0) 93 (93.0) 0.44*
Female 2 (4.0) 5 (10.0) 7 (7.0)
Weight (kg) 75.6±9.7 72.7±10.4 74.2±10.1 0.15
Smoking status
Non-smoker 30 (60.0) 26 (52.0) 56 (56.0) 0.42
Smoker 20 (40.0) 24 (48.0) 44 (44.0)
Opium consumption
No 39 (78.0) 38 (76.0) 77 (77.0) 0.81
Yes 11 (22.0) 12 (24.0) 44 (23.0)
Alcohol use
No 43 (86.0) 42 (84.0) 85 (85.0) 0.78
Yes 7 (14.0) 8 (16.0) 15 (15.0)
Underlying illness
None 45 (90.0) 43 (86.0) 88 (88.0) 0.68*
Diabetes 1 (2.0) 1 (2.0) 2 (2.0)
Pulmonary 1 (2.0) 2 (4.0) 3 (6.0)
Hypertension 1 (2.0) 0 (0.0) 1 (1.0)
Liver 1 (2.0) 0 (0.0) 1 (1.0)
Other 1 (2.0) 4 (8.0) 5 (5.0)
Ramsay sedation scale
4 47 (94.0) 49 (98.0) 96 (96.0) 0.62*
5 3 (6.0) 1 (2.0) 4 (4.0)
Data were reported as mean ± standard deviation or frequency (%).
Double-drug protocol: midazolam + fentanyl + placebo; triple-drug protocol: midazolam + fentanyl + lidocaine.
Table 2: Outcome of the studied patients
Variable Double-drug group (n=50) Triple-drug group (n=50) P
Visual analogue scale
Before treatment 8.3±1.3 8.2±1.2 0.55
After treatment 0.6±0.9 0.4±0.8 0.24
Success rate* 35 (70.0) 41 (82.0) 0.16
Side effects
None 47 (94.0) 45 (90.0) 0.78
Dysrhythmia 1 (2.0) 1 (2.0)
Apnea 2 (4.0) 2 (4.0)
SPO2<90% 0 (0.0) 2 (4.0)
Midazolam dosage (mg/kg) 5.9±2.7 5.9±2.5 0.97
Fentanyl dosage (µg/kg) 256.0±115.3 246.0±117.7 0.42
Data were reported as mean ± standard deviation or frequency (%).
*: Success rate was defined as complete analgesia (visual analogue scale=0)
Double-drug protocol: midazolam + fentanyl + placebo; Triple-drug protocol: midazolam + fentanyl + lidocaine.
the studied patients was 27.3±8.9 years (93.0% male). The 2
groups were not significantly different regarding age (p=0.71)
and sex (p=0.44) distribution, smoking (0.42), drug abuse
(p=0.81) and alcohol abuse (p=0.81) (table 1). Most of the pa-
tients (90% in the group with double-drug protocol and 86%
in the group with triple-drug protocol) had no history of un-
derlying illnesses (p=0.68).
Mean VAS score before the initiation of treatment in the
groups under treatment with double-drug and triple-drug
protocols were 8.3±1.3 and 8.2±1.2, respectively (p=0.52) and
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Table 3: Number needed to treat as well as absolute and relative risk
reduction of the triple-drug protocol
Variable Value
Pain reduction
Number needed to treat (n) 9
Absolute risk reduction 12.0%
Relative risk reduction 0.15
Adverse events
Number needed to harm (n) 25
Absolute risk reduction 4.0%
Relative risk reduction 0.04
after treatment these measures reached 0.6±0.9 and 0.4±0.8
(p=0.24). Using the double-drug regimen led to 35 (70%)
cases of complete analgesia, while this rate was 41 (82%)
cases in the triple-drug group (p=0.16) (table 2). Number
needed to treat calculated was 9 cases. This means that about
one in every 9 patients in treatment arm will benefit from the
treatment (table 3).
The most important side-effects observed included dys-
rhythmia (1 patient in double-drug treatment and 1 patient
in triple-drug treatment), apnea (2 patients in each group)
and SPO2<90% (2 patients in triple-drug group) (p=0.78) (ta-
ble 2). Number needed to harm was 25 cases. In other words,
for every 25 patients treated with the triple-drug regimen, 1
case of SPO2<90% is observed (table 3).
4. Discussion
Findings of the present study showed that adding IV lido-
caine to the IV midazolam + fentanyl drug combination does
not provide additional benefit in PSA for anterior shoulder
reduction.
Previous studies had indicated the effectiveness of intra-
articular prescription of lidocaine in decreasing the pain fol-
lowing shoulder reduction. In this regard, a meta-analysis
in 2009 showed that using intra-articular lidocaine is a safe
and effective method compared to old methods (22). In the
present study, combination of midazolam + fentanyl alone
has a high efficiency in sedation of patients and the pain
score of the patients has reduced 7.7 points on average (be-
tween 4 and 10 points) (table 2). Therefore, using IV lidocaine
prescription in combination with these drugs could not pro-
vide more effectiveness.
In a study, Kim et al. showed that prescription of 1.5 mg/kg
lidocaine as a bolus and single-dose IV injection and con-
tinuing it as 2 mg/kg in each hour leads to a significant de-
crease in pain and reduction in the amount of fentanyl used
compared with normal saline group after lumbar micro-
discectomy (24). The reason for the difference between the
results of that study and the present study can be the con-
tinuous infusion of lidocaine in the study by Kim et al., while
in the present study only a single bolus dose was prescribed.
This major difference has led to contradicting results. The ev-
idence for this statement is hidden in the treatment mecha-
nism of lidocaine infusion. IV infusion of the mentioned drug
with 1-2 mg/kg dose per hour maintains the plasma concen-
tration of the mentioned drug at a level that is not toxic and
provides sympathomimetic and analgesic effects (25) an ef-
fect that is not seen in the single-dose strategy.
In addition to the effectiveness of a treatment regimen, its
adverse side-effects are also of special importance. The find-
ings of the present study indicate that the prevalence of side-
effects after prescription of midazolam + fentanyl is not sig-
nificantly different from midazolam + fentanyl + lidocaine
group. In addition, number needed to harm calculated for
triple-drug regimen was 25 patients. However, the major
difference between the 2 drug regimens in manifestation of
side-effects was observed regarding SPO2<90%. Since simul-
taneous prescription of IV lidocaine and fentanyl leads to
intensification of fentanyl side-effects, especially depression
of central nervous system, the reason for the difference ob-
served regarding hypoxia between the 2 groups can be sought
in the interference of lidocaine with the effects of fentanyl.
However, hypoxia is a common side-effect in procedural se-
dations. For example, a meta-analysis showed that hypoxia
is the most important side-effect of using sedation and its
prevalence is 40.2 people in every 1000 cases. This side-
effect is immediately relieved with prescription of oxygen
and is therefore easily managed in emergency departments
(6). One of the limitations of the present study is its short
follow-up duration. Shoulder reduction is a painful proce-
dure and in many cases, after the half-life of sedative drugs
passes, pain restarts and troubles the patient. The half-lives
of drugs used vary; therefore, if the patients would be fol-
lowed for a longer period of time (not just until they were
completely conscious) the findings might have been differ-
ent.
5. Conclusion
Findings of the present study showed that addition of a bo-
lus and single-dose of IV lidocaine to the combination of IV
midazolam + fentanyl does not provide additional analgesia
and sedation in reduction of anterior shoulder dislocation in
patients presenting to the emergency department.
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